1. Home
  2. Category
  3. Treatment Types

Targeted Therapies

Article

Ocular Toxicity of Tyrosine Kinase Inhibitors

Mary Elizabeth Davis
ONF 2016, 43(2), 235-243 DOI: 10.1188/16.ONF.235-243
Purpose/Objectives: To review common tyrosine kinase inhibitors, as well as their ocular side effects and management. Data Sources: A comprehensive literature search was conducted using CINAHL®, PubMed, and Cochrane databases for articles published since 2004 with the following search terms: ocular...
0
No votes yet
Read this Article
Article

Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors

Kristen Kreamer
Debbie Riordan
CJON 2015, 19(6), 734-742 DOI: 10.1188/15.CJON.734-742
Background: The development of targeted therapies has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), with new clinical trials and therapies consistently providing new information. This rapidly changing field mandates ongoing education for nursing professionals whose...
0
No votes yet
Read this Article
Article

An Oncology Nurses’ Guide to New Targeted Agents for Metastatic Colorectal Cancer

Keith McIntyre
CJON 2015, 19(5), 571-579 DOI: 10.1188/15.CJON.571-579
Background: Colorectal cancer (CRC) that has metastasized before being discovered, or reoccurs following surgery, remains a major treatment challenge. Trials have established the usefulness of antiangiogenic agents and new regimens in prolonging survival in patients with advanced disease. In the...
3
Average: 3 (2 votes)
Read this Article
Quality

Minimizing Staff Exposure to Antineoplastic Agents During Intravesical Therapy

Clara C. Beaver
Morris A. Magnan
CJON 2015, 19(4), 393-395 DOI: 10.1188/15.CJON.393-395
Exposure to chemotherapy is a daily risk for nurses in oncology infusion centers. Although significant advances have been made in developing systems to make IV administration of antineoplastic agents safer, less attention has been given to developing systems to minimize exposure risk during...
0
No votes yet
Read this Article
Article

Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer

Josephine Divers
Joyce O’Shaughnessy
CJON 2015, 19(4), 468-474 DOI: 10.1188/15.CJON.468-474
Background: The mammalian target of rapamycin (mTOR) inhibitor everolimus is approved (in combination with exemestane) for the treatment of postmenopausal women with advanced hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer resistant to endocrine therapy...
0
No votes yet
Read this Article

Questions, Concerns or Requests

We're just a click away for assistance.